Godavari Drugs Ltd
Incorporated in 1987, Godavari Drugs Ltd manufactures and sale of Active Pharmaceutical Ingredients and their intermediates[1]
- Market Cap ₹ 124 Cr.
- Current Price ₹ 122
- High / Low ₹ 135 / 69.7
- Stock P/E 32.5
- Book Value ₹ 74.8
- Dividend Yield 0.00 %
- ROCE 6.69 %
- ROE 6.38 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -12.4%
- The company has delivered a poor sales growth of -2.91% over past five years.
- Company has a low return on equity of 10.1% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 150 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55 | 71 | 76 | 64 | 84 | 96 | 123 | 161 | 160 | 157 | 113 | 106 | |
| 49 | 67 | 70 | 60 | 78 | 90 | 113 | 150 | 150 | 143 | 102 | 95 | |
| Operating Profit | 6 | 4 | 5 | 4 | 5 | 6 | 10 | 11 | 10 | 13 | 12 | 10 |
| OPM % | 11% | 6% | 7% | 6% | 7% | 6% | 8% | 7% | 6% | 8% | 10% | 10% |
| 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |
| Interest | 1 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 5 | 2 | 3 | 1 | 2 | 2 | 6 | 7 | 5 | 7 | 6 | 5 |
| Tax % | 23% | 38% | 33% | 37% | 31% | 13% | 28% | 25% | 23% | 20% | 22% | 19% |
| 4 | 1 | 2 | 1 | 1 | 2 | 4 | 5 | 4 | 6 | 4 | 4 | |
| EPS in Rs | 4.85 | 1.79 | 2.40 | 1.10 | 1.61 | 2.66 | 5.48 | 6.97 | 5.03 | 7.37 | 5.82 | 4.04 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -3% |
| 3 Years: | -13% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -2% |
| 3 Years: | 2% |
| TTM: | -13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 15% |
| 3 Years: | 12% |
| 1 Year: | 26% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| Last Year: | 6% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 |
| Reserves | 6 | 7 | 9 | 10 | 11 | 13 | 17 | 22 | 26 | 31 | 36 | 66 |
| 8 | 16 | 16 | 19 | 22 | 28 | 30 | 23 | 36 | 58 | 64 | 76 | |
| 13 | 21 | 24 | 27 | 33 | 36 | 36 | 49 | 52 | 38 | 35 | 48 | |
| Total Liabilities | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 | 200 |
| 7 | 9 | 13 | 15 | 15 | 14 | 22 | 26 | 25 | 27 | 33 | 30 | |
| CWIP | 0 | 1 | 0 | 1 | 2 | 9 | 1 | 0 | 9 | 18 | 30 | 57 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 27 | 41 | 43 | 47 | 57 | 61 | 68 | 75 | 87 | 90 | 81 | 114 | |
| Total Assets | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 | 200 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6 | -5 | 5 | 4 | 4 | 6 | 1 | 11 | 13 | 18 | 11 | 1 | |
| -0 | -2 | -3 | -3 | -2 | -7 | -1 | -5 | -9 | -13 | -20 | -26 | |
| 6 | 7 | -2 | -0 | -1 | 0 | 0 | -6 | -4 | -6 | 8 | 37 | |
| Net Cash Flow | 0 | 0 | 0 | 1 | -0 | -0 | 0 | 1 | 1 | -0 | -0 | 12 |
| Free Cash Flow | -6 | -7 | 1 | 0 | 1 | -1 | -0 | 6 | 4 | 5 | -9 | -26 |
| CFO/OP | -101% | -101% | 108% | 109% | 73% | 108% | 26% | 110% | 143% | 146% | 105% | 19% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87 | 126 | 117 | 152 | 148 | 137 | 134 | 126 | 132 | 138 | 136 | 150 |
| Inventory Days | 84 | 67 | 70 | 100 | 93 | 84 | 55 | 28 | 57 | 62 | 125 | 217 |
| Days Payable | 79 | 108 | 124 | 171 | 171 | 144 | 112 | 121 | 132 | 96 | 128 | 163 |
| Cash Conversion Cycle | 92 | 85 | 63 | 81 | 70 | 78 | 78 | 33 | 58 | 105 | 133 | 204 |
| Working Capital Days | 63 | 44 | 40 | 47 | 38 | 31 | 46 | 32 | 23 | 9 | 11 | 42 |
| ROCE % | 32% | 16% | 17% | 11% | 12% | 12% | 18% | 18% | 14% | 14% | 10% | 7% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agro / Industrial Waste Fuel Consumption Tons |
|
|||||||||||
| Capital Work in Progress (CWIP) ₹ Lakhs |
||||||||||||
| Electricity Consumption '000 KWH |
||||||||||||
| Total Permanent Employees Number |
||||||||||||
| Export Presence (Number of Countries) Number |
||||||||||||
| R&D Expenditure (Percentage of Turnover) % |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 May - Please find the enclosed newspaper publication for your information
-
Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue For The Quarter Ended March 31, 2026
27 May - No deviation in preferential issue fund utilization for quarter and year ended March 31, 2026; ₹4,411.73 lakh raised.
- Financial Results For Period Ended 31St March,2026 27 May
-
Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting Held On Wednesday 27Th Day Of May,2026
27 May - Board approved FY26 audited results, unmodified audit opinion, auditor appointments, and AGM on 25 September 2026.
-
Board Meeting Intimation for Board Meeting Intimation For The Fourth Quarter And Financial Year Ended March 31, 2026
22 May - Board meeting on May 27, 2026 to approve audited standalone results for FY2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company is in the business of Manufacturing APIs, drug intermediaries, and fine chemicals and caters to the global Life Science Industry. It has an active Loan License and Contract Manufacturing tie-ups with multinational companies for APIs and drug intermediates